Biotech trade groups have filed a legal challenge targeting the Trump administration’s Global Benchmark for Efficient Drug Pricing demonstration, known as GLOBE. The Biotechnology Innovation Organization (BIO) and two California-based groups seek to halt the Medicare pilot, arguing it exceeds statutory authority. The complaint was filed in the U.S. District Court for the Northern District of California, calling into question how peer-country benchmarks would translate into Medicare reimbursement decisions. The Centers for Medicare and Medicaid Services had not responded at the time of the report. For biotech, the case highlights a direct link between policy design and commercial strategy—especially for therapies facing global pricing scrutiny. The outcome could influence contract pricing, launch planning, and how sponsors model revenue under benchmark-based constraints. The filing also signals that industry stakeholders are increasingly willing to litigate policy mechanics—not just individual pricing outcomes.